Featured Story | By Kyle LaHucik With new FDA safety restrictions on JAK inhibitors—specifically Pfizer's Xeljanz, AbbVie’s Rinvoq and Lilly’s Olumiant—the next generation of JAK therapies could face an uphill battle to the finish line. read more |
| |
|---|
|
Top Stories By Kyle LaHucik Roche is making a big play in off-the-shelf cell therapies, putting up a potential $3 billion in biobucks for Adaptimmune to develop up to five cancer targets. Roche's Genentech unit will dish out $150 million upfront to Adaptimmune to develop and commercialize allogeneic cell therapies for up to five shared cancer targets, the companies said Tuesday. read more By Annalee Armstrong During the pandemic, special purpose acquisition companies were popping up like weeds ready to spread out in the biotech garden. Things have slowed down, but dozens of shell companies are still waiting for the right biotech to strike. read more By Nick Paul Taylor The gene therapy space has taken yet another hit. Labor Day, just days after the FDA convened a panel to discuss the cancer risk of gene therapies, BioMarin revealed the regulator has slapped a clinical hold on a phase 1/2 study over a safety signal seen in mice. read more By Ben Adams Oncology biotech Exelixis is mourning the deaths of two key members of its company after losing its sales leader and CMO in the same week. read more By Nick Paul Taylor Piece by piece, Amgen and AstraZeneca are building the case for their potential asthma blockbuster. The latest brick to fall into place comes from a new slice of phase 3 data, which suggests tezepelumab may be particularly effective in a subgroup of severe asthma patients. read more By Annalee Armstrong Pliant Therapeutics’ anti-fibrotic drug seems to have engaged its target in a mid-stage lung disease clinical trial, which was enough to excite investors and push the biotech's shares up. But the company's watchers will have to wait to see if the drug actually works to correct idiopathic pulmonary fibrosis, or IPF. read more By Ben Adams Roche, like so many others in the field, has seen major setbacks in trying to hunt new drugs for Huntington’s disease, but it’s brushing off a recent flop and signing up with a new partner in the hopes of trying again. read more By Amirah Al Idrus Psychedelics-focused biotech Journey Colab bagged $12 million to start its first human trial in 2022. The funding will push its lead program, a treatment based on a hallucinogenic compound found in some species of cactus, into phase 1. read more By Andrea Park The AI algorithm could help hospitals not only determine how many ventilators they’ll need, but also be more precise and proactive as they plan out each COVID patient’s treatment. read more By Beth Snyder Bulik Friendly epinephrine? Meet Neffy, ARS Pharmaceuticals’ nasal spray epinephrine to treat severe allergic reactions to food, medicines and insect bites. Neffy, now awaiting FDA approval, aims to flip the script on past epinephrine autoinjector marketing that focused on fear around the severe reactions called anaphylaxis. read more By Andrea Park The new algorithm could help guide placement of brain-stimulating devices to treat neurological conditions ranging from epilepsy to Parkinson’s disease to obsessive compulsive disorder. read more Resources Sponsored By: Unlearn AI Read Unlearn’s whitepaper to learn about how novel trial designs with Digital Twins enable more efficient clinical trials, with higher power and smaller required sample sizes. Sponsored by: Patheon by Thermo Fisher Scientific Choose the right AAV platform for your viral vector-based therapy Sponsored by: XIFIN inc. Download the Value of Precision Medicine Informatics (PMI) Initiatives report to learn about the technology, data types, and the value derived from more than 100 PMI initiatives. Sponsored by: EVERSANA Today’s economics do not allow manufactures to keep making decisions in an antiquated way. They need to challenge tradition & deliver faster, cheaper, successful launches. Learn how. Sponsored by: Thermo Fisher Scientific Thermo Fisher Scientific introduces a new NK cell culture medium designed to support feeder-free, high-yield growth for cell therapy applications. Sponsored by: Cascade Chemistry by Aceto Read four customer success stories and four success factors that helped move pharmaceutical customers of Cascade Chemistry by Aceto quickly and effectively to clinic with trial-ready APIs. Sponsored by: ConnectiveRx Topple barriers to getting patients started on therapy. Guide them with mobile. Sponsored by: Box Read Get to Know Cloud Content Management for Life Sciences and learn how to eliminate silos across all workflows, from R&D to commercialization. Sponsored by: Catalent Learn about drug product process development challenges and risks, the difference between innovator and biosimilar drug product process development, and more during the drug product process development phase. Sponsored by: Catalent Get insights on key considerations for a successful tech transfer process for manufacturing a biologic drug product, including a case study on overcoming challenges in a process transfer for a sterile diluent. | 
